Boehringer Ingelheim and Click Therapeutics shared data from the pivotal phase III CONVOKE study (NCT05838625) of CT-155 (BI 3972080), an investigational prescription digital therapeutic (PDT) used as ...
CONVOKE was the first and only pivotal trial to show a statistically significant reduction in experiential negative symptoms of schizophrenia as an adjunct to standard of care antipsychotic therapy, ...
RIDGEFIELD, Conn. and NEW YORK, Oct. 13, 2025 /PRNewswire/ -- Boehringer Ingelheim and Click Therapeutics today shared data from the pivotal Phase III CONVOKE study (NCT05838625) of CT-155 (BI 3972080 ...
Air Force Technology on MSN
BAE Systems, Turkish Aerospace to pursue UAS opportunities
BAE Systems and Turkish Aerospace have entered a MoU to examine opportunities for joint development in uncrewed air systems ...
Air Force Technology on MSN
BAE Systems’ legal bid fails to stop strikes at F-35 and Typhoon hubs
Following legal action, the UK High Court has ruled that industrial action at BAE Systems' UK fighter hubs can go ahead.
Hundreds of aerospace engineers working for a major defence company are set to walk out in a row over pay. The Unite union said its 5,000 members working for BAE Systems at sites in Warton and ...
German drugmaker Boehringer Ingelheim and Click Therapeutics said their phase 3 trial of a prescription digital therapeutic for the negative symptoms of schizophrenia met its primary endpoint. Data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback